We conclude that the 5-HT1A agonist and 5-HT2A antagonist monotherapies alone could reduce the core symptoms of ADHD by altering the expression of DA1 and DA2 neuroreceptors in prefrontal cortex, striatum, and substantia nigra. Here, HTR2A is linked to attention deficit-hyperactivity disorder.